 |
Dr. GPCR PodcastAuthor: Dr. Yamina Berchiche
We bring you closer to dedicated scientists who work tirelessly to help understand GPCR pathophysiology. Language: en Genres: Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it Trailer: |
Listen Now...
Building GPCR Assays That Reflect Real Biology
Episode 189
Tuesday, 8 September, 2026
The biggest signal is not the same as the truest one. Jane Lamerdin and Gaurav Agrawal of Eurofins DiscoverX on what actually makes a GPCR assay trustworthy.Overexpress a receptor and you get a big, convenient readout that drifts away from what happens in a living cell. Across nearly three decades of building cell-based assays, Lamerdin and Agrawal have learned that physiological relevance, not raw expression, is the real benchmark, and increasingly it is what regulators expect too. This conversation moves from the company's roots in cyclic AMP and arrestin biology to the receptors that refuse to yield an assay, the long road from a discovery screen to potency and lot release, and why the obesity drug wave brought the largest target class back to the front of drug discovery.What you will take away:Why physiological relevance beats maximal expression, and how that raises the technical barWhat it takes to move one assay from discovery all the way to potency and lot releaseWhy some GPCRs, from adhesion receptors to orphans stuck in the ER, refuse to cooperateHow decades of documented failures keep a portfolio from reinventing dead endsWhy obesity and GLP-1 biology put GPCRs back at the center of drug discoveryDr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/Eurofins DiscoverX: https://www.ecosystem.drgpcr.com/eurofins-discoverxMembership and Pricing: https://www.ecosystem.drgpcr.com/university-pricing
